Nektar Therapeutics reported $3.13M in Interest Income for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Income Change
Agios Pharmaceuticals AGIO:US USD 6.49M 2.67M
Baxter International BAX:US USD 8M 3M
BioCryst Pharmaceuticals BCRX:US USD 2.7M 944K
Biogen BIIB:US USD 49.9M 26M
Bluebird Bio BLUE:US USD 383K 209K
Cara Therapeutics CARA:US USD 968K 303K
Esperion Therapeutics ESPR:US USD 900K 100K
Exelixis EXEL:US USD 16.99M 7.49M
Ironwood Pharmaceuticals IRWD:US USD 5.45M 2.64M
Karyopharm Therapeutics KPTI:US USD 1.33M 676K
Nektar Therapeutics NKTR:US USD 3.13M 1.08M
Pfizer PFE:US USD 137M 67M
Sarepta Therapeutics SRPT:US USD 9.13M 4.35M
Xencor XNCR:US USD 2.07M 689K